Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cantor Fitzgerald
US Army
Fuji
Daiichi Sankyo
Accenture
Cerilliant
Argus Health
Express Scripts

Generated: November 16, 2018

DrugPatentWatch Database Preview

Atorvastatin calcium; ezetimibe - Generic Drug Details

« Back to Dashboard

What are the generic sources for atorvastatin calcium; ezetimibe and what is the scope of atorvastatin calcium; ezetimibe patent protection?

Atorvastatin calcium; ezetimibe is the generic ingredient in two branded drugs marketed by Watson Labs Teva and Merck Sharp Dohme, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are sixty-two drug master file entries for atorvastatin calcium; ezetimibe.

US Patents and Regulatory Information for atorvastatin calcium; ezetimibe

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-004 May 3, 2013 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Watson Labs Teva EZETIMIBE AND ATORVASTATIN CALCIUM atorvastatin calcium; ezetimibe TABLET;ORAL 206084-003 Apr 26, 2017 RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-003 May 3, 2013 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Watson Labs Teva EZETIMIBE AND ATORVASTATIN CALCIUM atorvastatin calcium; ezetimibe TABLET;ORAL 206084-002 Apr 26, 2017 RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-002 May 3, 2013 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for atorvastatin calcium; ezetimibe

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-002 May 3, 2013 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-001 May 3, 2013 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-001 May 3, 2013 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-004 May 3, 2013 ➤ Sign Up ➤ Sign Up
Merck Sharp Dohme LIPTRUZET atorvastatin calcium; ezetimibe TABLET;ORAL 200153-003 May 3, 2013 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cantor Fitzgerald
US Army
Fuji
Daiichi Sankyo
Accenture
Cerilliant
Argus Health
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.